Semaglutide forms head-to-head
| Form | Manufacturer | FDA Indication | Cash price |
|---|
| Ozempic | Novo Nordisk | Type 2 diabetes | ~$935-$1,000/mo |
| Wegovy | Novo Nordisk | Chronic weight management; CV risk reduction | $349/mo (NovoCare self-pay, read October 15, 2026) |
| Rybelsus | Novo Nordisk | Type 2 diabetes (oral) | ~$935/mo |
| Compounded semaglutide | 503A compounding pharmacy | Not FDA-approved | $119-From $179/mo (read October 15, 2026) |
Pivotal trial results
- STEP-1 (NEJM 2021, PMID 33567185) — semaglutide 2.4 mg: 14.9% weight loss / 68 weeks vs 2.4% placebo
- SUSTAIN-6 (NEJM 2016, PMID 27633186) — semaglutide CV safety in T2D + high CV risk
- SELECT (NEJM 2023, PMID 37952131) — 20% MACE reduction in non-diabetic adults with overweight/obesity + CVD
- FLOW (NEJM 2024, PMID 38785189) — 24% reduction in major kidney/CV events in T2D + CKD
- SURPASS-2 (NEJM 2021, PMID 34170647) — tirzepatide ~47% greater weight loss vs semaglutide 1 mg
Detailed head-to-head pages